rev.health · Fundraise V1
Estimated enterprise value at Year 5 (2031) and Year 10 (2036) for each seed-raise scenario — $2M, $3M, and $4M — built on the financial model and benchmarked to current healthcare-IT revenue multiples and 2022–2026 M&A comparables.
Confidential · Illustrative · Not an offer or financial adviceHow to read this
Healthcare-IT companies are valued primarily on a multiple of recurring revenue (ARR). We take each scenario's exit-ARR run-rate from the financial model, project it to Year 10 at a stated, decelerating growth rate, and apply a three-point multiple band drawn from today's market.
The comparables
| Comparable | Event | Multiple | Relevance |
|---|---|---|---|
| NextGen Healthcare | Thoma Bravo take-private, $1.8B (2023) | 2.8× rev | Mature, slow-growth EHR — the floor |
| athenahealth | Bain / Hellman & Friedman, $17B (2022) | ~10–12× rev | Scaled, profitable ambulatory platform |
| Healthcare SaaS (sector) | 2026 market range | 5–12× rev | Switching costs, recurring revenue |
| AI-native premium | vs. non-AI peers | +20–30% | Proprietary data + workflow lift |
| Tempus (high-growth AI) | Public, ~85% growth | 9.3× rev | What growth + AI commands |
| Abridge / Ambience (ambient AI) | $5.3B / $1.25B private valuations (2025) | venture | Strategic appetite for the category |
Sources: Bain & Hellman & Friedman / athenahealth (2022); 2026 HealthTech M&A multiples (Nelson Advisors); SaaS valuation multiples (Aventis); State of Health AI 2026 (Bessemer).
Inputs from the model
| Scenario | Practices (2031) | Year 5 ARR (2031) | Year 10 ARR (2036)* | Yr 6–10 CAGR |
|---|---|---|---|---|
| $2M — Lean | 450 | $24M | $70M | 24% |
| $3M — Focused | 650 | $35M | $115M | 27% |
| $4M — Full | 850 | $46M | $165M | 29% |
*Year-10 ARR projects the model's 2031 exit-ARR forward five years at the stated decelerating CAGR (down from the 80%+ early-scaling rates). Pricing held at $399/physician, $299/PA-NP per month + 3.5% of collections.
The numbers
| Scenario | ARR | Conservative (3×) | Base (6×) | Upside (10×) |
|---|---|---|---|---|
| $2M | $24M | $72M | $144M | $240M |
| $3M | $35M | $105M | $210M | $350M |
| $4M | $46M | $138M | $276M | $460M |
| Scenario | ARR | Conservative (3×) | Base (6×) | Upside (10×) |
|---|---|---|---|---|
| $2M | $70M | $210M | $420M | $700M |
| $3M | $115M | $345M | $690M | $1.15B |
| $4M | $165M | $495M | $990M | $1.65B |
Visualizing the base case
Bars scaled to the largest base-case value. The $3M Focused scenario is the headline plan; the $4M Full scenario is the upside path. Conservative and upside bands shown in the tables above.
Liquidity paths
rev.health sits in the most actively-consolidated corner of health IT. There are four realistic liquidity paths, sequenced roughly by scale:
Incumbents need an AI-native ambulatory platform they can't build fast enough: Oracle Health, Veradigm, athenahealth, and PE-backed consolidators (NextGen/Thoma Bravo, Tebra, Waystar). Ambient-AI leaders (Abridge, Ambience) and payers/retail health (Optum, CVS, Amazon) want the workflow surface and the longitudinal data. Strategic buyers pay 20–40% above financial sponsors.
Best fit: any scenario once ARR clears ~$30–50M and the data asset is proven.
PE loves profitable, recurring health IT — exactly the model's Year-5 profile. Thoma Bravo (NextGen), Bain & Hellman & Friedman (athenahealth), Vista, and Francisco Partners are actively consolidating ambulatory EHR/RCM. rev.health is either a platform to build on or a tuck-in that lifts a portfolio's growth rate.
Best fit: $3M / $4M scenarios at $100–500M EV with clean margins.
At $150M+ ARR with durable growth and a profitability line of sight, the public markets are open — the path taken by Phreesia, Waystar, and Tempus. This is the maximum-value, maximum-independence outcome.
Best fit: $4M scenario's Year-10 trajectory (~$165M ARR).
The model is cash-generative by Year 5 (base case). Founders can decline early offers, run a dividend recap or secondary to take chips off the table, and compound — preserving the option on a larger exit later.
Best fit: any scenario where growth and margins stay strong.
Caveats
Valuation scales linearly with both ARR and multiple, so the ranges are wide by design. The multiple a buyer pays is driven by growth rate, net revenue retention (110–120% typical in healthcare SaaS), gross margin (model holds 77%), and the strength of the proprietary-data moat. RCM revenue (3.5% of collections) is usage-based and may be valued at a lower multiple than pure subscription, which would pull the blended figure toward the conservative band; a clean-subscription mix pushes it toward the upside.